Humana heads into its third-quarter report with a seasonal loss widely expected and the real debate elsewhere. The managed-care company has spent the year arguing that cost discipline, steadier medical trend and better quality scores are rebuilding its Medicare Advantage margins. The November 6 release, due before the open, is the first chance to test that story after the star ratings blackout that management said would last until CMS's final release in October. That timing gives this quarter more weight than the headline number alone suggests.
Wall Street expects a loss of $1.03 per share, against a $3.24 profit a year ago, on revenue of about $40.46 billion. That revenue figure would be up nearly 24% from the year-ago quarter and roughly in line with the $40.87 billion reported last quarter. The swing from a $7.61 profit in the second quarter to a loss reflects how Medicare Advantage earnings work: benefit costs build as members meet deductibles later in the year, which pushes profits toward the first half. The whisper number calls for a smaller loss of $0.85. That is a modest gap, but it tells you the informal bar sits above consensus, so merely matching the published estimate may not satisfy the market. For the full year, management has reaffirmed earnings of at least $9.00 per share. The Street sits at $9.46, about 5% above that floor. That signals confidence that the guide is conservative, but it also means any hint that Humana is drifting toward the minimum would read as a disappointment.
The previous call improved mainly because the evidence got better, not because guidance rose. Management said the consolidated operating cost ratio fell 120 basis points in the second quarter and held to its target of roughly 150 basis points of improvement for the year. It credited centralized utilization management, outsourcing and the Care Plus integration with hundreds of millions of dollars in value. It also cited slight favorability in medical trend, concentrated among value-based providers where inpatient admissions and unit costs were both lower. Continued progress on the cost ratio, along with a third quarter that shows the favorable inpatient trend has not reversed, would validate that narrative. A cost spike, especially in pharmacy, where management already expects drug trend to rise into 2027, would challenge it. Investors should also listen for reaffirmation that individual Medicare Advantage margins remain on track to double this year excluding star ratings.
Star ratings are the larger swing factor. Last quarter management offered its most concrete evidence yet. It said the rate of improvement beat historical growth on 11 of 12 quality measures tied to the 2028 bonus year, and it described 2029 quality work running about 5% ahead of the prior year's pace. With industry cut points now presumably public, the call should show whether that operational progress actually translated into ratings. The answer drives the path to the company's target of at least 3% pre-tax margin in 2028. Also on the agenda are the roughly 600,000 members affected by 2027 plan exits, of whom management hopes to recapture about 40% or more, and the disruption from CMS ending the Part D premium stabilization demonstration. Early enrollment commentary ahead of the December 10 investor update would help frame both.
Sentiment has shifted noticeably. Bullish readings climbed to about 30% from barely 2% before the last report, and the stock has gained 6.1% since then, slightly ahead of the S&P 500. At $411.87, shares sit well above the 200-day moving average near $307 but roughly 10% below the post-earnings high of $456.50. The rally has eased, though the stock is far calmer than in the prior quarter's $214 to $429 range.
In the end, the quarter's loss matters less than whether Humana can show that cost savings and trend favorability are durable and that its quality work showed up in the ratings. If both hold, the $9.00 floor looks conservative and the margin-recovery thesis stays intact. If either slips, the recent optimism has room to unwind.